Evidence map›Paper›PMID 41452132›Full record

ReviewEssays in biochemistry2025

Clues for glues: from serendipity to nature's blueprints in degrader discovery.

Zuzanna Kozicka

Abstract readReview
In one paragraph

Review in Essays in biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Zuzanna KozickaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, U.S.A.ORCID 0000-0003-0085-6565

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular glue degraders (MGDs) are small molecules that promote interactions between an E3 ligase and a target protein, reconfiguring recognition to trigger proteasome-mediated degradation. Their discovery has so far been largely serendipitous - either recognized in retrospect or uncovered through 'needle-in-a-haystack' screening - but systematic strategies are beginning to emerge. This review frames two complementary routes for discovery. The first views MGDs as modular - typically anchored on either the ligase or the target - which allows the chemical search space to be biased toward such anchoring. Ligase-directed strategies derivatize known ligase binders, as demonstrated for cereblon (CRBN) and now beyond. Conversely, recent target-directed strategies remodel inhibitors into glues through solvent-exposed elaboration, effectively inverting the classical design paradigm. Both approaches tilt discovery toward chemotypes more likely to yield glue activity. Second, biology provides its own guideposts: certain protein pairs appear especially predisposed to stabilization. Endogenous degrons, mutational lesions, and transferable 'glueprints' of surface topology all point to contexts in which small molecules might act as functional surrogates - repairing hypomorphs, mimicking hypermorphs, or creating neomorphs. MGDs, therefore, exemplify how small molecules can reprogram recognition logic by transforming latent compatibilities into selective degradation. Together, these insights help rationalize past discoveries and suggest possible blueprints for more systematic ones ahead.

Indexed as

Drug DiscoveryUbiquitin-Protein LigasesAnimalsHumansProteolysisUbiquitin-Protein Ligasesdrug discovery and designmedicinal chemistrymolecular glue degraderstargeted protein degradationubiquitin ligases

Identifiers

PMID41452132
PMCPMC12794332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.